comprehensive -WSS

comprehensive

author：Wikipedia 2025-10-01 23:39:02 - browse：4

A view of different flags of the European Union Members. -- first opinion coverage from STAT — Ronald Wittek, Pool Photo via AP

Today, the criteria used to assess the clinical value of new pharmaceuticals and medical devices varies widely across Europe, making it more challenging for biopharma companies to efficiently launch products in multiple countries and contributing to the disparities in access across the continent.

But change is on the horizon: In less than 15 months, the European Union will establish and begin to implement a standardized, pan-EU framework, which all 27 of member states will be required to use to assess the clinical evidence of newly submitted products or devices. A key pillar of the EU’s Regulation on Health Technology Assessment (HTA), the Joint Clinical Assessment (JCA) aims to establish a single, transparent process to reduce redundant practices and bring life science innovation faster to patients in Europe — no matter where they live.

In a longstanding problem in Europe, access to — and the availability of — medication varies across the member states. For example, in Germany, 87% of products approved by the European Medicines Agency (EMA) have full availability (the product gained access on the public reimbursement list without any restrictions to the patient population). In Poland, that figure drops to 8%, according to a report published by the European Federation of Pharmaceutical Industries. Meanwhile, there is a tremendous difference in the gap between an oncology therapy receiving marketing authorization and a formal positive reimbursement decision, ranging from an average of 86 days in Denmark to 981 days in Latvia.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Would Medicare drug price negotiations stall in a shutdown?

WSS

Feed a cold, starve a fever? Here’s what science says

It was time to plan for my old age. If only I could stop crying

Cigna to pay $172 million to settle Medicare Advantage fraud probe

Sweden knocks USA out of World Cup in penalty kicks

Trump used to be more articulate. What could explain the change?

How CRISPR works, explained in two minutes

focus

comprehensive

focus

Hepatitis C has a cure — but many Americans still lack access to it

Mindstrong's demise and the future of mental health care

Apple is now the first public company to be valued at $3 trillion

Paxlovid rebound happens. Why and to whom are still a mystery

Affirmative action in medical school literally saved lives

Trump used to be more articulate. What could explain the change?

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

STAT Virtual Event: How to Increase Diversity in Clinical Trials

State Dept. review finds Biden bears some blame for Afghanistan failures

Severe weather updates: 1 million customers without power in 11 states as storms pummel East Coast

focus

Trump used to be more articulate. What could explain the change?

Intercept Pharmaceuticals sells itself for less than $1 billion

Medicare drug price negotiation program allowed for now

Menendez indictment could see pharma lose a key ally

Failure, not just success, should guide future doctors

Severe weather updates: 1 million customers without power in 11 states as storms pummel East Coast

focus

hotspot

hotspot

knowledge